MAPT and early-onset autosomal dominant Alzheimer disease: Thus, PET imaging agents that bind to aggregated tau have the potential to serve as a biomarker for disease severity of Alzheimer’s disease (AD) and tauopathies, and may be useful for monitoring disease progression and therapeutic effects.